<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01981486</url>
  </required_header>
  <id_info>
    <org_study_id>B3441008</org_study_id>
    <nct_id>NCT01981486</nct_id>
  </id_info>
  <brief_title>A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults</brief_title>
  <official_title>A Phase I, Placebo Controlled, Randomized, Subject-And Investigator-Blind, Sponsor-Open, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05180999 In Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to
      evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999
      administered twice daily over 14 days. Exploratory measures of PDE2 inhibition will also be
      evaluated in blood and blister fluid.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0-12 hours post-dose on Day 1</time_frame>
    <description>Single dose Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0-12 hours post-dose on Day 1</time_frame>
    <description>Single dose Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>0-12 hours post-dose on Day 1</time_frame>
    <description>Single dose AUCtau</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady-State (Cmax,ss)</measure>
    <time_frame>0-12 hours post-dose on Day 14</time_frame>
    <description>Steady-state Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration at Steady-State (Tmax,ss)</measure>
    <time_frame>0-12 hours post-dose on Day 14</time_frame>
    <description>Steady-state Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration at Steady-State (Cmin,ss)</measure>
    <time_frame>0-12 hours post-dose on Day 14</time_frame>
    <description>Steady-state Cmin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to End of Dosing Interval at Steady-State (AUCtau,ss)</measure>
    <time_frame>0-12 hours post-dose on Day 14</time_frame>
    <description>Steady-state AUCtau</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>0-48 hours post-final dose on Day 14</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>0-48 hours post-final dose on Day 14</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0-48 hours post-final dose on Day 14</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio (Racc)</measure>
    <time_frame>0-12 hours post-dose on Days 1 and 14</time_frame>
    <description>Ratio of Day 14 AUCtau to Day 1 AUCtau</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount Excreted in Urine (Ae)</measure>
    <time_frame>0-12 hours post-dose on Day 14</time_frame>
    <description>Amount of drug excreted in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Dose Excreted in Urine (Ae%)</measure>
    <time_frame>0-12 hours post-dose on Day 14</time_frame>
    <description>Percent of total dose excreted in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr)</measure>
    <time_frame>0-48 hours post-dose on Day 14</time_frame>
    <description>Renal clearance is a quantitative measure of the rate at which a drug substance is removed from the blood via the renal route.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of metabolites of PF-05180999 in urine and plasma</measure>
    <time_frame>0-12 hours post-dose on Day 14</time_frame>
    <description>Metabolite identification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Leukocyte Levels and Leukocyte Subpopulations in Blister Fluid and Blood</measure>
    <time_frame>Day 13 and Day 14</time_frame>
    <description>Leukocyte levels in blister fluid and blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cytokine Levels in Blister Fluid</measure>
    <time_frame>Day 13 and Day 14</time_frame>
    <description>Cytokine levels in blister fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-Averaged Area Under the Effect Curve (AUEC/t) for Platelet cGMP and cAMP</measure>
    <time_frame>0-12 hours post-dose on Day 1 and Day 14</time_frame>
    <description>Time-averaged area under the effect curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC/t Ratio</measure>
    <time_frame>0-12 hours post-dose on Day 1 and Day 14</time_frame>
    <description>Ratio of Day 14 AUEC/t to Day 1 AUEC/t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary 6beta-hydroxycortisol/cortisol ratio</measure>
    <time_frame>Day 14</time_frame>
    <description>Urinary marker of CYP3A induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 4beta-hydroxycholesterol/cholesterol ratio</measure>
    <time_frame>Day 14</time_frame>
    <description>Plasma marker of CYP3A induction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05180999</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified-release tablets of PF-05180999</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>BID modified-release tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05180999 Tablets</intervention_name>
    <description>BID modified-release tablets (20 to 240 mg BID)</description>
    <arm_group_label>PF-05180999</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female (of non-childbearing potential) subjects between the ages
             of 18 and 55 years

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)

        Exclusion Criteria:

          -  Subjects with Gilbert's disease or screening laboratory test results that deviate from
             the upper and/or lower limits of the reference or acceptable range. The exception is
             that all liver function tests must not exceed the upper limit of normal.

          -  Subjects with evidence of, or history of, hepatic disorder, including acute or chronic
             hepatitis B or hepatitis C.

          -  Subjects with very light skin or very dark skin (at the discretion of the
             investigator).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3441008&amp;StudyName=A%20Study%20Of%20The%20Safety%2C%20Tolerability%2C%20And%20Pharmacokinetics%20Of%20Multiple%20Doses%20Of%20PF-05180999%20In%20Healthy%20Adults</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-05180999</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>migraine</keyword>
  <keyword>PDE2</keyword>
  <keyword>cAMP</keyword>
  <keyword>cGMP</keyword>
  <keyword>cantharidin</keyword>
  <keyword>blister</keyword>
  <keyword>CYP3A induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

